全脑同期加量调强放疗治疗脑转移瘤的临床研究

doi:10.3760/cma.j.issn.1673-422X.2018.06.003

摘要/Abstract

摘要： 目的评价全脑同期加量调强放疗（IMRT）治疗脑转移瘤的疗效及安全性。方法选择2015年1月至2017年1月在广西壮族自治区玉林市第一、二人民医院住院放疗的120例脑转移瘤患者。采用信封法将患者随机分为三维适形序贯加量组（3DCRT组，n=60）和调强同步加量组（IMRT组，n=60），比较两组的疗效及患者放疗前后精神状态变化。结果 3DCRT组患者中位生存期为11.5个月，半年、1年生存率分别为83.3%、35.0%；IMRT组患者中位生存期为12.9个月，半年、1年生存率分别为86.7%、38.3%，两组预后差异无统计学意义（χ2=0.143，P=0.705）。3DCRT组完全缓解8例，部分缓解38例，病情稳定11例，疾病进展3例，IMRT组分别为9例、40例、9例和2例，两组近期疗效差异无统计学意义（Z=-0.641，P=0.520）。单因素分析结果显示，递归分隔分析（RPA）分级（χ2=53.484，P＜0.001）、颅外病灶的控制情况（χ2=13.392，P＜0.001）、中线结构是否偏移（χ2=4.427，P=0.035）为预后相关因素。多因素分析结果显示，RPA分级（HR=2.631，95%CI为1.884~3.673，P＜0.001）、颅外病灶的控制情况（HR=1.697，95%CI为1.034~2.786，P=0.037）、中线结构是否偏移（HR=1.787，95%CI为1.118~2.856，P=0.015）是影响患者生存率的独立预后因素。3DCRT组放疗前后简短精神状态量表评分分别为（27.12±2.42）分、（26.08±2.42）分，差异有统计学意义（t=2.723，P=0.009）；IMRT组放疗前后评分分别为（26.57±3.09）分、（27.20±2.46）分，差异无统计学意义（t=-1.610，P=0.113）。结论全脑同期加量IMRT是多发脑转移瘤的一种有效治疗手段，可缓解患者症状，延长生存期，提高生命质量。

关键词: 肿瘤转移, 放射疗法, 调强适形, 癌, 颅脑照射

Abstract: Objective To evaluate the efficacy and safety of intensity modulated radiation therapy (IMRT) for wholebrain radiotherapy with simultaneous integrated boost for brain metastases. MethodsFrom January 2015 to January 2017, 120 patients with brain metastases undergoing hospital radiotherapy at the First People′s Hospital and the Second People′s Hospital of Yulin City of Guangxi Zhuang Autonomous Region were randomly divided into three dimensional conformal radiation therapy (3DCRT) group (n=60) and IMRT group (n=60) by envelope method. The curative effects of the two groups and the changes of patient′s mental states before and after radiotherapy were compared. ResultsThe median survival times of patients in 3DCRT group was 11.5 months, and the 6 months and 1 year survival times rates were 83.3% and 35.0% respectively. The median survival times of patients in IMRT group was 12.9 months, and the 6 months and 1 year survival rates were 86.7% and 38.3% respectively. There was no significant difference in prognosis between the two groups (χ2=0.143, P=0.705). There were 8 cases with complete remission, 38 cases with partial remission, 11 cases with stable disease, 3 cases with progressive disease in 3DCRT group, and there were 9, 40, 9, 2 cases in IMRT group respectively. There was no statistically significant difference in shortterm efficacy between the two groups (Z=-0.641, P=0.520). Univariate analysis results showed that recursive partitioning analysis (RPA) classification (χ2=53.484, P＜0.001), extracranial lesions control (χ2=13.392, P＜0.001), whether the midline offset (χ2=4.427, P=0.035) were prognostic factors. Multivariate analysis results showed that RPA classification (HR=2.631, 95%CI: 1.8843.673, P＜0.001), extracranial lesions control (HR=1.697, 95%CI: 1.0342.786, P=0.037), whether the midline offset (HR=1.787, 95%CI: 1.1182.856, P=0.015) were the independent prognostic factors for the overall survival. According to the results of activities of minimental state examination, the scores of 3DCRT group before and after radiotherapy were 27.12±2.42 and 26.08±2.42 respectively, with a significant difference (t=2.723, P=0.009); and the scores of IMRT group before and after radiotherapy were 26.57±3.09 and 27.20±2.46 respectively, with no significant difference (t=-1.610, P=0.113). ConclusionIMRT for wholebrain radiotherapy with simultaneous integrated boost is an effective treatment for multiple brain metastases, which can relieve symptoms, prolong survival time and improve quality of life.

Key words: Neoplasm metastasis, Radiotherapy, intensity modulated, Carcinoma, Cranial irradiation

朱海生，严浩林，阙丽琳，甘媚，梁雷锋，何林. 全脑同期加量调强放疗治疗脑转移瘤的临床研究[J]. 国际肿瘤学杂志, 2018, 45(6): 331-336.

Zhu Haisheng, Yan Haolin, Que Lilin, Gan Mei, Liang Leifeng, He Lin. Clinical study of intensity modulated radiation therapy for wholebrain radiotherapy with simultaneous integrated boost for brain metastases[J]. Journal of International Oncology, 2018, 45(6): 331-336.

参考文献

［1］ Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidencebased clinical practice guideline［J］. J Neurooncol, 2010, 96(1): 17-32. DOI: 10.1007/s11060-009-0060-9. ［2］ Patil CG, Pricola K, Sarmiento JM, et al. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases［J］. Cochrane Database Syst Rev, 2017, 9: CD006121. DOI: 10.1002/14651858.CD006121.pub4. ［3］胡银祥, 卢冰, 韩蕾, 等. 非小细胞肺癌3～5个脑转移瘤优选调强放疗的可行性研究［J］. 中华放射肿瘤学杂志, 2012, 21(4): 369-373. DOI: 10.3760/cma.j.issn.1004-4221.2012.04.022. ［4］ Murray KJ, Scott C, Greenberg HM, et al. A randomized phase Ⅲ study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104［J］. Int J Radiat Oncol Biol Phys, 1997, 39(3): 571-574. ［5］张九成, 皮国良, 何海翠, 等. 56例非小细胞肺癌脑转移行全脑调强放疗的疗效和预后因素分析［J］. 华中科技大学学报: 医学版, 2014, 43(3): 331-335. DOI: 10.3870/j.issn.1672-0741.2014.03.020. ［6］ Lagerwaard FJ, van der Hoorn EA, Verbakel WF, et al. Wholebrain radiotherapy with simultaneous integrated boost to multiple brain metastases using volumetric modulated arc therapy［J］. Int J Radiat Oncol Biol Phys, 2009, 75(1): 253-259. DOI: 10.1016/j.ijrobp.2009.03.029. ［7］朱虹, 吕博, 李海云, 等. 脑转移瘤放射治疗的预后因素分析及预后模型的建立［J］. 中国癌症杂志, 2014, 24(6): 457462. DOI: 10.3969/j.issn.10073969.2014.06.010. ［8］ Ali AN, Ogunleye T, Hardy CW, et al. Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme［J］. Radiat Oncol, 2014, 9: 20. DOI: 10.1186/1748-717X-9-20. ［9］ Gondi V, Hermann BP, Mehta MP, et al. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or lowgrade adult brain tumors［J］. Int J Radiat Oncol Biol Phys, 2012, 83(4): e487e493. DOI: 10.1016/j.ijrobp.2011.10.021. ［10］ Ghia A, Tomé WA, Thomas S, et al. Distribution of brain metastases in relation to the hippocampus: implications for neurocognitive functional preservation［J］. Int J Radiat Oncol Biol Phys, 2007, 68(4): 971-977. DOI: 10.1016/j.ijrobp.2007.02.016. ［11］ Gondi V, Tome WA, Marsh J, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during wholebrain radiotherapy: safety profile for RTOG 0933［J］. Radiother Oncol, 2010, 95(3): 327-331. DOI: 10.1016/j.radonc.2010.02.030. ［12］ Marsh JC, Herskovic AM, Gielda BT, et al. Intracranial metastatic disease spares the limbic circuit: a review of 697 metastatic lesions in 107 patients［J］. Int J Radiat Oncol Biol Phys, 2010, 76(2): 504512. DOI: 10.1016/j.ijrobp.2009.02.038. ［13］王靖, 卢冰, 胡银祥, 等. 非小细胞肺癌脑转移调强放射治疗可行性研究［J］. 中华肿瘤防治杂志, 2013, 20(16): 1253-1256. ［14］ Slade AN, Stanic S. The impact of RTOG 0614 and RTOG 0933 trials in routine clinical practice: the US survey of utilization of memantine and IMRT planning for hippocampus sparing in patients receiving whole brain radiotherapy for brain metastases［J］. Contemp Clin Trials, 2016, 47: 74-77. DOI: 10.1016/j.cct.2015.12.013. ［15］ Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stemcell compartment during wholebrain radiotherapy for brain Metastases (RTOG 0933): a phase Ⅱ multiinstitutional trial［J］. J Clin Oncol, 2014, 32(34): 3810-3816. DOI: 10.1200/JCO.2014.57.2909.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[5]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[6]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[7]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[8]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[9]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[10]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[11]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[12]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[13]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[14]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[15]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.